CA29668H7085 - Common Stock
ESSA PHARMA INC
NASDAQ:EPIX (11/4/2024, 8:05:31 PM)
After market: 1.57 -0.06 (-3.68%)1.63
+0.23 (+16.43%)
ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 50 full-time employees. The company went IPO on 2021-02-22. The firm is focused on developing proprietary therapies for the treatment of patients with prostate cancer. Its lead candidate, EPI-7386, is an oral, small molecule that inhibits the N-terminal domain of the androgen receptor (AR). The firm is completing the initial Phase I clinical development of EPI-7386 as a monotherapy treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). The firm is also developing ANITen bAsed Chimera (ANITAC) AR NTD degraders to suppress androgen biology.
ESSA PHARMA INC
999 West Broadway, Suite 720
Vancouver BRITISH COLUMBIA V5Z 1K5
P: 17783310962
CEO: David Parkinson
Employees: 50
Website: https://www.essapharma.com/
Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume.
Let's have a look at what is happening on the US markets after the closing bell on Friday. Below you can find the top gainers and losers in today's after hours session.
Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to...
Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion...
Combination of masofaniten plus enzalutamide continues to be well tolerated with durable reductions in PSA in patients with mCRPC Phase 2 dose expansion...
Here you can normally see the latest stock twits on EPIX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: